Motzer et al [1] recently reported results for a primary disease-free survival (DFS) analysis of the PROTECT phase 3 trial in which pazopanib (starting dose 800 mg subsequently reduced to 600 mg once daily owing to the high treatment discontinuation rate) failed to show a DFS benefit (primary endpoint) compared to placebo in the adjuvant setting. These results are in line with those obtained in ASSURE and more generally with other trials evaluating the role of angiogenesis inhibitors in different malignancies such as colon and breast cancer and melanoma.

Massari F, D.N.V. (2017). Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.09.008. EUROPEAN UROLOGY, 8, 72-73.

Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.09.008

Massari F;Di Nunno V;Ardizzoni A
2017

Abstract

Motzer et al [1] recently reported results for a primary disease-free survival (DFS) analysis of the PROTECT phase 3 trial in which pazopanib (starting dose 800 mg subsequently reduced to 600 mg once daily owing to the high treatment discontinuation rate) failed to show a DFS benefit (primary endpoint) compared to placebo in the adjuvant setting. These results are in line with those obtained in ASSURE and more generally with other trials evaluating the role of angiogenesis inhibitors in different malignancies such as colon and breast cancer and melanoma.
2017
Massari F, D.N.V. (2017). Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.09.008. EUROPEAN UROLOGY, 8, 72-73.
Massari F, Di Nunno V, Ardizzoni A
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/678791
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact